Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Immunology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Cutaneous T-Cell Lymphoma Clinical Trials

A listing of Cutaneous T-Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (20) clinical trials

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

PRIMARY OBJECTIVES: I. To determine if vitamin D replacement in vitamin D insufficient patients with newly diagnosed untreated diffuse large B-cell lymphoma (DLBCL) can improve event free survival at 12 months to be equivalent to that of a control population of vitamin D sufficient patients. (Study I) II. To assess ...

Phase N/A

Blood Urine and Tissue Collection for Cutaneous Lymphoma Eczema and Atopic Dermatitis Research

The purpose of this study is to provide a central mechanism for monitoring access to peripheral blood, urine, and skin specimens obtained from CTCL, eczema, and atopic dermatitis patients to monitor: immunologic assays/flow cytometry tumor progression/regression genomic studies proteomic studies others germane to the advancement of CTCL treatment

Phase N/A

Topical Romidepsin in Treating Patients With Stage I or Stage II Cutaneous T-Cell Non-Hodgkin's Lymphoma

OBJECTIVES: Primary - Determine the maximum tolerated dose of topical romidepsin when escalated by concentration, frequency, and body surface area in patients with stage IA, IB, or IIA cutaneous T-cell non-Hodgkin's lymphoma. - To monitor the skin and systemic toxicity of this drug in these patients. Secondary - Determine histone ...

Phase

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for up to 12 ...

Phase

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given that the median age at diagnosis is 55-60 years and frequently present compromised skin in these patients, which increases the risk of infection. Therefore, we propose a clinical study with allogeneic HSCT using a unique non-myeloablative preparative regimen, TLI/ATG, ...

Phase

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

PRIMARY OBJECTIVES: I. To evaluate the safety of brentuximab vedotin and rituximab in patients with lymphoid malignancies that are cluster of differentiation (CD) 30 positive (+) and/or Epstein-Barr virus (EBV)+, and to determine the recommended phase 2 dose (RP2D) of the combination. (Phase I) II. To evaluate the efficacy, as ...

Phase

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

This is a multicenter, open-label, single-arm study of E7777 in participants with recurrent or persistent Cutaneous T-Cell Lymphoma (CTCL). The study will consist of an initial lead-in phase (in which a dose of E7777 will be selected), followed by the Main Study. Participants will move through three phases while on ...

Phase

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax in Combination With Doxil for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

This a multi-center, single arm, open-label, Phase I dose-finding and preliminary efficacy study of the combination of the histone deacetylase inhibitor romidepsin (Istodax) in combination with doxorubicin HCl liposomal (Doxil) for adult patients with relapsed or refractory cutaneous T-cell lymphoma after at least one prior line of systemic therapy. STUDY ...

Phase

Phase I Study of Romidepsin Gemcitabine Oxaliplatin and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

The purpose of this research study is to find the maximum tolerated dose of a drug called romidepsin when given with a treatment regimen called GemOxD. GemOxD is a routine treatment for certain types of lymphoma, and involves the administration of three drugs: gemcitabine, oxaliplatin, and dexamethasone. In addition to ...

Phase

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

PRIMARY OBJECTIVES: I. To evaluate the efficacy of the combination of romidepsin plus lenalidomide in patients with previously untreated peripheral T-cell lymphoma (PTCL). SECONDARY OBJECTIVES: I. Evaluate the safety of the combination of romidepsin and lenalidomide. II. Further evaluate efficacy of the combination of romidepsin and lenalidomide. III. Evaluate the ...

Phase